Groowe Groowe / Newsroom / LSTA
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

LSTA News

Lisata Therapeutics, Inc. Common Stock

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc.

globenewswire.com
NATH LSTA SNCY VTYX

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

globenewswire.com
LSTA

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

globenewswire.com
LSTA

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’

globenewswire.com
LSTA

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

globenewswire.com
LSTA

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

globenewswire.com
LSTA

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

globenewswire.com
LSTA

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

globenewswire.com
LSTA